Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tacrolimus sustained-release tablets and preparation method thereof

A technology for tacrolimus and sustained-release tablets, applied in the field of water-insoluble drug tacrolimus sustained-release tablets and its preparation, can solve problems such as complex processes, achieve simple prescription processes, low production costs, and maintain blood drug concentrations Effect

Active Publication Date: 2017-01-11
SHENYANG PHARMA UNIVERSITY
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The method has complicated prescription and process, and needs to use organic solvent in the preparation process

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tacrolimus sustained-release tablets and preparation method thereof
  • Tacrolimus sustained-release tablets and preparation method thereof
  • Tacrolimus sustained-release tablets and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Embodiment 1: Tacrolimus solid dispersion

[0050] Prescription 1:

[0051] Tacrolimus 10mg

[0052] Glyceryl Behenate 150mg

[0053] Weigh glyceryl behenate, heat and stir in a water bath at 80°C to melt, then lower the temperature to 70°C, add tacrolimus, continue stirring for 3 hours, slowly cool to room temperature, crush, pass through a 60-mesh sieve, and place at 40°C Put it down for 24h. 4h dissolution rate was 95%. After being placed at 40°C for 10 days, the dissolution rate in 4 hours was 80%. It shows that the physical stability of the prescription is not good, and the dissolution rate obviously decreases after being placed.

Embodiment 2

[0054] Embodiment 2: tacrolimus solid dispersion

[0055] Prescription 2:

[0056] Tacrolimus 10mg

[0057] Glyceryl Behenate 75mg

[0058] Macrogol Glyceryl Stearate 75mg

[0059] Weigh glyceryl behenate and polyethylene glycol stearate, heat and stir in a water bath at 80°C to melt, then lower the temperature to 70°C, add tacrolimus, continue stirring for 3 hours, slowly cool to room temperature, and pulverize , passed through a 60-mesh sieve, and placed at 40°C for 24 hours. The dissolution rate in 0.5h is 98%; after 10 days at 40°C, the dissolution rate in 0.5h is 20%. It shows that the physical stability of the prescription is not good, and the dissolution rate obviously decreases after being placed.

Embodiment 3

[0060] Embodiment 3: tacrolimus solid dispersion

[0061] Prescription 3:

[0062] Tacrolimus 10mg

[0063] Glyceryl Behenate 125mg

[0064] Stearic acid 25mg

[0065] Weigh glyceryl behenate and stearic acid, heat, stir and melt in a water bath at 80°C, lower the temperature to 70°C, add tacrolimus, continue stirring for 3 hours, slowly cool to room temperature, pulverize, pass through a 60-mesh sieve, Place it at 40°C for 24h. 4h dissolution rate was 90%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a water-insoluble drug, namely, tacrolimus sustained-release tablets. The tacrolimus sustained-release tablets take a lipid material, a water-soluble material, a stabilizer and the like as a carrier, and are prepared by adopting a melting method to prepare a solid dispersion which is stable in properties and is capable of obviously improving the dissolution rate of tacrolimus, blending the prepared solid dispersion with a sustained-release material, a diluent and other pharmaceutical necessities, and tabletting the mixture. The tacrolimus sustained-release tablets have the unique advantages that (1) the sustained-release tablets are simple in formulation and technology, and can be formed by directly tabletting powder without adding auxiliary materials such as a lubricating agent and a binding agent; (2) the low-melting-point lipid material is used, the medicine can be directly dissolved in the molten lipid material and is then cooled and cured, and a volatile organic solvent does not need to be treated, so that the production safety is greatly improved, and the environmental pollution is reduced; (3) the quaternary solid dispersion formed by the medicine, the lipid material, the water-soluble material and the stabilizer is good in stability, so that the dissolution rate of the tacrolimus sustained-release tablets does not change significantly after the tacrolimus sustained-release tablets are placed for a period of time; (4) the tacrolimus sustained-release tablets can reduce the times of administration, thus reducing the fluctuation of plasma concentration.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and relates to a water-insoluble drug tacrolimus sustained-release tablet and a preparation method thereof. Background technique [0002] At present, improving the dissolution rate and bioavailability of poorly water-soluble drugs is a difficult problem in the field of pharmaceutical preparation research and pharmaceutical production. [0003] Tacrolimus (tacrolimus; FK 506) is a non-dissociative hydrophobic macrolide antibiotic that was first isolated from the fermentation broth of Streptomyces tsukubaensis by Fujisawa Company in Japan. Its molecular formula is C 44 h 69 NO 12 , relative molecular mass is 804.02, melting point is 127-129°C, soluble in methanol, ethanol, acetonitrile and other organic reagents, insoluble in water. [0004] Tacrolimus belongs to the BCS class II drugs, and the main absorption sites of oral administration are in the jejunum and ileum, and the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/22A61K47/38A61K47/26A61K47/14A61K47/10A61K47/32A61P31/04
Inventor 徐晖刘力孙璐王荣雪李佳赵美慧
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com